PMID: 6539561Jun 1, 1984Paper

Chronic verapamil therapy in pediatric and young adult patients with hypertrophic cardiomyopathy

The American Journal of Cardiology
R L SpicerA Rosenthal

Abstract

Oral verapamil, 5.2 +/- 1.1 mg/kg/day (range 2.8 to 7), was administered to 13 pediatric patients with hypertrophic cardiomyopathy for 13 +/- 6 months (range 2 to 20). The patients had significant symptomatic improvement on verapamil therapy. Murmur intensity diminished in 6 patients during therapy and left ventricular (LV) electromotive forces on the electrocardiogram diminished in 4, increased in 5 and did not change in 4. Exercise endurance increased from 8.4 +/- 3.9 to 10.9 +/- 2.8 minutes (p less than 0.01). Seven patients had ST-segment depression (0.38 +/- 0.28 mV) before verapamil therapy, which improved after verapamil therapy in 5 (0.24 +/- 0.17 mV, p less than 0.02). Of 4 patients with exercise-induced ventricular ectopic activity, 3 had diminution or abolishment of ectopy following verapamil. By echocardiography, the patients had an increase in LV end-diastolic dimension from 3.4 +/- 0.7 to 3.9 +/- 0.8 cm (p less than 0.01), with no significant change in shortening fraction (46.1 +/- 8.0% vs 44.6 +/- 8.0%). When adjusted for body size and age there was a significant decrease in LV septal thickness (from 106 +/- 70 to 45 +/- 52% of predicted normal values, p less than 0.05) and LV posterior wall thickness (from 40 +/...Continue Reading

References

Nov 1, 1978·The American Journal of Cardiology·G I FiddlerE R Giuliani
Jul 1, 1979·British Heart Journal·M KaltenbachY Petersen

❮ Previous
Next ❯

Citations

Apr 28, 1999·Pediatric Clinics of North America·J A Towbin
Mar 15, 1997·Journal of the American College of Cardiology·F RishiR M Campbell
Dec 19, 1998·Journal of the American College of Cardiology·A T YetmanB W McCrindle
Sep 10, 1998·Cardiology in the Young·A M Moran, S D Colan
Feb 1, 1996·Acta Paediatrica Japonica; Overseas Edition·A IshizawaS I Homma
Apr 1, 1986·British Heart Journal·F CasazzaM Morpurgo
Jul 1, 1991·The American Journal of Cardiology·K M McDonald, B Maurer
Aug 24, 2010·Fundamental & Clinical Pharmacology·Ingegerd Ostman-Smith
Jan 10, 2012·Congenital Heart Disease·Shiraz A Maskatia
Jul 27, 2021·Circulation Journal : Official Journal of the Japanese Circulation Society·Hiroaki KitaokaUNKNOWN Japanese Circulation Society Joint Working Group

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.